Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
Tyra Biosciences (Nasdaq: TYRA) announced the acceptance of two abstracts for presentation at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco. The first presentation covers TYRA-200, featuring a multicenter, open-label, first-in-human study for advanced intrahepatic cholangiocarcinoma and other solid tumors with FGFR2 gene alterations. Dr. Robin Kate Kelley from UC San Francisco will present this study.
The second presentation focuses on TYRA-430, described as the first reversible FGFR4/3 inhibitor designed to address challenges in FGF19-driven hepatocellular carcinoma treatment, to be presented by Dr. Ronald Swanson. Both presentations are scheduled for January 24, 2025, from 11:30 AM to 1:00 PM PST.
Tyra Biosciences (Nasdaq: TYRA) ha annunciato l'accettazione di due abstract per la presentazione al Simposio ASCO 2025 sui Tumori Gastrointestinali a San Francisco. La prima presentazione riguarda TYRA-200, caratterizzata da uno studio multicentrico, aperto e primo al mondo sull'uomo per il colangiocarcinoma intraepatico avanzato e altri tumori solidi con alterazioni del gene FGFR2. La Dott.ssa Robin Kate Kelley dell'UC San Francisco presenterà questo studio.
La seconda presentazione si concentra su TYRA-430, descritto come il primo inibitore reversibile di FGFR4/3 progettato per affrontare le sfide nel trattamento del carcinoma epatocellulare guidato da FGF19, presentato dal Dott. Ronald Swanson. Entrambe le presentazioni sono programmate per il 24 gennaio 2025, dalle 11:30 alle 13:00 PST.
Tyra Biosciences (Nasdaq: TYRA) anunció la aceptación de dos resúmenes para presentación en el Simposio ASCO 2025 sobre Cánceres Gastrointestinales en San Francisco. La primera presentación cubre TYRA-200, que presenta un estudio multicéntrico, de etiqueta abierta y primer en humanos para colangiocarcinoma intrahepático avanzado y otros tumores sólidos con alteraciones del gen FGFR2. La Dra. Robin Kate Kelley de UC San Francisco presentará este estudio.
La segunda presentación se centra en TYRA-430, descrito como el primer inhibidor reversible de FGFR4/3 diseñado para abordar los desafíos en el tratamiento del carcinoma hepatocelular impulsado por FGF19, que será presentado por el Dr. Ronald Swanson. Ambas presentaciones están programadas para el 24 de enero de 2025, de 11:30 AM a 1:00 PM PST.
Tyra Biosciences (Nasdaq: TYRA)는 샌프란시스코에서 열리는 2025 ASCO 위장관 암 심포지엄에 발표할 두 개의 초록이 수락되었다고 발표했습니다. 첫 번째 발표는 TYRA-200에 관한 것으로, FGFR2 유전자 변이가 있는 진행성 간내 담관암 및 기타 고형 종양에 대한 다기관, 개방형, 첫 인간 연구를 포함합니다. UC 샌프란시스코의 로빈 케이트 켈리 박사가 이 연구를 발표할 예정입니다.
두 번째 발표는 TYRA-430에 초점을 맞추고 있으며, 이는 FGF19 기반 간세포암 치료의 어려움을 해결하기 위해 설계된 첫 번째 가역적 FGFR4/3 억제제로 설명됩니다. 로널드 스완슨 박사가 발표할 예정입니다. 두 발표는 2025년 1월 24일 오전 11시 30분부터 오후 1시까지 PST로 예정되어 있습니다.
Tyra Biosciences (Nasdaq: TYRA) a annoncé l'acceptation de deux résumés pour présentation lors du Symposium ASCO 2025 sur les Cancers Gastro-Intestinaux à San Francisco. La première présentation concerne TYRA-200, qui présente une étude multicentrique, ouverte et première chez l'homme pour le cholangiocarcinome intra-hépatique avancé et d'autres tumeurs solides avec des altérations du gène FGFR2. Le Dr Robin Kate Kelley de l'UC San Francisco présentera cette étude.
La deuxième présentation se concentre sur TYRA-430, décrit comme le premier inhibiteur réversible de FGFR4/3 conçu pour relever les défis dans le traitement du carcinome hépatocellulaire induit par FGF19, qui sera présenté par le Dr Ronald Swanson. Les deux présentations sont programmées pour le 24 janvier 2025, de 11h30 à 13h00 PST.
Tyra Biosciences (Nasdaq: TYRA) hat die Annahme von zwei Abstracts für die Präsentation beim 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco bekannt gegeben. Die erste Präsentation behandelt TYRA-200, welches eine multizentrische, offene, erste Studie am Menschen für fortgeschrittenes intrahepatisches Cholangiokarzinom und andere solide Tumoren mit FGFR2-Genveränderungen umfasst. Dr. Robin Kate Kelley von der UC San Francisco wird diese Studie präsentieren.
Die zweite Präsentation konzentriert sich auf TYRA-430, das als der erste reversible FGFR4/3-Inhibitor beschrieben wird, der entwickelt wurde, um die Herausforderungen bei der Behandlung von FGF19-getriebenem hepatocellulärem Karzinom anzugehen, und wird von Dr. Ronald Swanson präsentiert. Beide Präsentationen sind für den 24. Januar 2025 von 11:30 Uhr bis 13:00 Uhr PST geplant.
- Two abstracts accepted for presentation at major industry conference (ASCO GI)
- Development progress of two drug candidates (TYRA-200 and TYRA-430) targeting different cancer types
- None.
Details of the poster presentations are below:
Title: "A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201)"
Abstract: TPS646
Presenting Author: Robin Kate Kelley, MD, University of California San Francisco
Session: Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 24, 2025, 11:30 AM – 1:00 PM PST, Level 1, West Hall
Title: "TYRA-430: First reversible FGFR4/3 inhibitor designed to overcome current challenges in FGF19-driven hepatocellular carcinoma treatment"
Abstract: 583
Presenting Author: Ronald Swanson, Ph.D., Tyra Biosciences
Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date/Time: January 24, 2025, 11:30 AM – 1:00 PM PST, Level 1, West Hall
The abstracts related to these posters and additional information can be found on the ASCO GI website.
About TYRA-200
TYRA-200 is an oral, investigational, FGFR1/2/3 inhibitor with potency against activating FGFR2 gene alterations and resistance mutations. The Phase 1 clinical study of TYRA-200, SURF201 (Study in PrevioUsly treated and Resistant FGFR2+ Cholangiocarcinoma and Other Advanced Solid Tumors) (NCT06160752), is a multi-center, open label study designed to evaluate the maximum tolerated dose (MTD) and the recommended Phase 2 dose of TYRA-200, as well as to evaluate the preliminary antitumor activity of TYRA-200. SURF201 is currently enrolling and dosing adults with advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating alterations in FGFR2.
About TYRA-430
TYRA-430 is an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. The US Food and Drug Administration has cleared Tyra's Investigational New Drug application to proceed with a Phase 1 clinical study of TYRA-430. The Phase 1 study will be a multicenter, open-label, first-in-human study of TYRA-430 in advanced hepatocellular carcinoma (HCC) and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431).
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Forward-Looking Statements
TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential to develop next-generation precision medicines and for TYRA-300 to be first-in-class, and the potential safety and therapeutic benefits of our product candidates; the expected timing and phase of development of TYRA-300; and the potential for SNÅP to develop therapies in targeted oncology and genetically defined conditions. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: later developments with the FDA may be inconsistent with prior feedback from the FDA; we are early in our development efforts, have only recently begun testing TYRA-300 and TYRA-200 for oncology in clinical trials and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies and clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-poster-presentations-at-2025-asco-gastrointestinal-cancers-symposium-302357388.html
SOURCE Tyra Biosciences
FAQ
What are the two drug candidates TYRA is presenting at ASCO GI 2025?
When and where will TYRA present its research at ASCO GI 2025?
What is unique about TYRA-430's mechanism of action?
What type of study is being presented for TYRA-200?
